Genome-Wide Oligonucleotide Microarray Analysis of Gene-Expression Profiles of Taiwanese Patients with Anaplastic Astrocytoma and Glioblastoma Multiforme
Free accessResearch articleFirst published online October, 2008
Genome-Wide Oligonucleotide Microarray Analysis of Gene-Expression Profiles of Taiwanese Patients with Anaplastic Astrocytoma and Glioblastoma Multiforme
This study investigated the relationship between gene expression and disease based on the expression profiles of tissue-specific genes, with the aim of discovering the candidate genes associated with disease risk as diagnostic markers. The gene-expression profiles of approximately 20,000 genes from 4 anaplastic astrocytomas (AAs), 7 glioblastoma multiformes (GBMs), and 1 nontumor brain (NB) were analyzed by in situ—synthesized 60-mer oligonucleotide microarray. The signal intensity of each feature was measured by laser scanner, and gene expression was quantified as the tumor/NB intensity ratio. Gene expression was defined as having increased or decreased when the ratio was ≥1.5 or ≤ 0.67, respectively. In comparison with NB, 20 genes showed increased expression, and 32 showed decreased expression in AA, while 20 genes showed increased expression, and 164 showed decreased expression in GBM. This research indicates that changes in expression levels of 4 genes in AA and 6 genes in GBM may be useful diagnostic markers. Quantitative reverse transcription—polymerase chain reaction also supported the microarray results for the 6 selected genes. In conclusion, microarray images of excellent quality are of high data reproducibility using entirely standard procedures, and these genes may be associated with the molecular events leading to AA or GBM. (Journal of Biomolecular Screening 2008:912-921)
Tanwar MK, Gilbert MR, Holland EC: Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res2002;62:4364-4368.
2.
van den Boom J., Wolter M., Kuick R., Misek DE, Youkilis AS, Wechsler DS, et al: Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol2003;163:1033-1043.
3.
Rickman DS, Bobek MP, Misek DE, Kuick R., Blaivas M., Kurnit DM, et al: Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res2001;61: 6885-6891.
4.
Brat DJ, Mapstone TB: Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med2003;138: 659-668.
5.
Sterrenburg E., Turk R., Boer JM, van Ommen GB, den Dunnen JT: A common reference for cDNA microarray hybridizations . Nucleic Acids Res2002;30:e116.
6.
Kleihues P., Cavenee WK: Pathology and genetics of tumors of the nervous system. In: World Health Organization Classification of Tumors. France , Lyon: IARC Press, 2000.
Wang H., Wang H., Shen W., Huang H., Hu L., Ramdas L., et al: Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res2003;63:4315-4321.
9.
Golembieski WA, Rempel SA: cDNA array analysis of SPARC-modulated changes in glioma gene expression. J Neurooncol2002 ;60:213-226.
10.
Wang M., Wang T., Liu S., Yoshida D., Teramoto A.: The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol2003 ;20:65-72.
11.
Li YF, Sun HX, Wu GD, Du WN, Zuo J., Shen Y., et al: Protein kinase C/zeta (PRKCZ) gene is associated with type 2 diabetes in Han population of North China and analysis of its haplotypes. World J Gastroenterol2003;9:2078-2082.
12.
Anantharam V., Lehrmann E., Kanthasamy A., Yang Y., Banerjee P., Becker KG, et al: Microarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: relevance to oxidative damage in Parkinson's disease. Neurochem Int2007;50:834-847.
13.
Carter MG, Hamatani T., Sharov AA, Carmack CE, Qian Y., Aiba K., et al: In situ-synthesized novel microarray optimized for mouse stem cell and early developmental expression profiling. Genome Res2003;13:1011-1021.
14.
Presneau N. , Shen Z., Provencher D., Mes-Masson AM, Tonin PN: Identification of novel variant, 1484delG in the 3′UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors. Int J Oncol2005;26:1621-1627.
15.
Müller S., Kunkel P., Lamszus K., Ulbricht U., Lorente GA, Nelson AM, et al: A role for receptor tyrosine phosphatase zeta in glioma cell migration. Oncogene2003;22:6661-6668.
16.
Tojyo I., Yamaguchi A., Nitta T., Yoshida H., Fujita S., Yoshida T.: Effect of hypoxia and interleukin-1β on expression of tenascin-C in temporomandibular joint. Oral Dis2008;14:45-50.
17.
Sis B., Sağol O., Küpelioğlu A., Sokmen S., Terzi C., Fuzun M., et al: Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. Pathol Res Pract2004;200:379-387.
18.
Tanaka M., Yamazaki T., Araki N., Yoshikawa H., Yoshida T., Sakakura T., et al: Clinical significance of tenascin-C expression in osteosarcoma: tenascin-C promotes distant metastases of osteosarcoma. Int J Mol Med2000;5:505-510.
19.
Nishio T., Kawaguchi S., Yamamoto M., Iseda T., Kawasaki T., Hase T.: Tenascin-C regulates proliferation and migration of cultured astrocytes in a scratch wound assay. Neuroscience2005;132:87-102.
20.
Alvarez E., Zhou W., Witta SE, Freed CR: Characterization of the Bex gene family in humans, mice, and rats. Gene2005;357:18-28.
21.
Foltz G., Ryu GY, Yoon JG, Nelson T., Fahey J., Frakes A., et al: Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res2006;66:6665-6674.
22.
Guo Q., Xie J., Dang CV, Liu ET, Bishop JM: Identification of a large Myc-binding protein that contains RCC1-like repeats . Proc Natl Acad Sci U S A1998;95: 9172-9177.
23.
Wink MR, Lenz G., Braganhol E., Tamajusuku AS, Schwartsmann G., Sarkis JJ, et al: Altered extracellular ATP, ADP and AMP catabolism in glioma cell lines. Cancer Lett2003;198:211-218.
24.
MacDonald TJ , Pollack IF, Okada H., Bhattacharya S., Lyons-Weiler J.: Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. Methods Mol Biol2007;377:203-222.
25.
Rong Y., Hu F., Huang R., Mackman N., Horowitz JM, Jensen RL, et al: Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res2006;66:7067-7074.
26.
Pen A., Moreno MJ, Martin J., Stanimirovic DB: Molecular markers of extracellular matrix remodeling in glioblastoma vessels: microarray study of laser-captured glioblastoma vessels. Glia2007;55:559-572.
27.
Rempel SA, Golembieski WA, Fisher JL, Maile M., Nakeff A.: SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J Neurooncol2001;53:149-160.
28.
Lebedeva TV , Ohashi M., Huang A., Vasconcellos S., Flesch S., Yu N.: Emerging new alleles suggest high diversity of HLA-C locus. Tissue Antigens2005;65:101-106.
29.
van den Boom J., Wolter M., Blaschke B., Knobbe CB, Reifenberger G.: Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription-polymerase chain reaction. Int J Cancer2006;19:2330-2338.
30.
Nakagawa T. , Kabuto M., Kubota T., Kodera T., Sato K.: Production of amyloid beta protein precursor as a proteinase inhibitor by human astrocytic tumors. Anticancer Res1999;19:2963-2968.
